Optiray (Ioversol)

Ioversol contains a high concentration of iodine atoms, which strongly absorb X‑ray photons. When injected intravenously or intra‑arterially, it distributes throughout the vascular and extracellular spaces, increasing X‑ray attenuation in the targeted area. This creates a clear contrast between blood‑filled structures and surrounding tissues on the imaging scan.

The dose of Optiray is determined by the prescribing physician based on the specific imaging study, patient size, renal function, and clinical protocol. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal image quality while minimizing potential risks.

The safety of Optiray in pregnancy and lactation has not been fully established. It should only be used when the diagnostic benefit outweighs potential risks to the fetus or infant, and after careful consideration by the treating physician. Consultation with obstetric and neonatal specialists is recommended.

To order Optiray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Optiray (ioversol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other low‑osmolality agents, it provides similar image quality while potentially reducing the incidence of warmth sensations and mild adverse reactions.

Optiray should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the product, and ensure the container is sealed to maintain sterility until use.

Optiray is administered as a sterile solution for injection via the intravenous or intra‑arterial route. The injection is performed by qualified healthcare personnel using aseptic technique, typically through a peripheral or central venous catheter, and the rate of administration is adjusted according to the imaging protocol.

The most serious risks include severe allergic reactions such as anaphylaxis, acute kidney injury (contrast‑induced nephropathy), and profound hypotension. Patients with known iodine allergy, impaired renal function, or uncontrolled thyroid disease require careful assessment before receiving Optiray.

Optiray is contraindicated in patients with a documented severe hypersensitivity to ioversol or any iodinated contrast agent, those with uncontrolled hyperthyroidism or thyroid storm, and individuals with severe renal impairment where the risk of contrast‑induced nephropathy outweighs diagnostic benefit.